Bioatla Stock Today
| BCAB Stock | USD 0.34 0.02 6.25% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Bioatla is trading at 0.34 as of the 16th of March 2025, a 6.25 percent increase since the beginning of the trading day. The stock's open price was 0.32. Bioatla has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of December 2020 | Category Healthcare | Classification Health Care |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 58.02 M outstanding shares of which 3.83 M shares are currently shorted by private and institutional investors with about 3.46 trading days to cover. More on Bioatla
Moving together with Bioatla Stock
Moving against Bioatla Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bioatla Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioatla can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioatla's financial leverage. It provides some insight into what part of Bioatla's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioatla (BCAB) is traded on NASDAQ Exchange in USA. It is located in 11085 Torreyana Road, San Diego, CA, United States, 92121 and employs 65 people. Bioatla is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.95 M. Bioatla conducts business under Biotechnology sector and is part of Health Care industry. The entity has 58.02 M outstanding shares of which 3.83 M shares are currently shorted by private and institutional investors with about 3.46 trading days to cover.
Bioatla currently holds about 178.12 M in cash with (104.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bioatla Probability Of Bankruptcy
Ownership AllocationBioatla holds a total of 58.02 Million outstanding shares. 30% of Bioatla outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bioatla Ownership Details
Bioatla Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Deutsche Bank Ag | 2024-12-31 | 525.4 K | |
| Massachusetts Financial Services Company | 2024-12-31 | 515.8 K | |
| Geode Capital Management, Llc | 2024-12-31 | 420 K | |
| Norges Bank | 2024-12-31 | 389.1 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 373.1 K | |
| Gsa Capital Partners Llp | 2024-12-31 | 350.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 214.2 K | |
| State Street Corp | 2024-12-31 | 151.4 K | |
| Jane Street Group Llc | 2024-12-31 | 149.3 K | |
| Anson Funds Management Lp | 2024-12-31 | 4.6 M | |
| Highbridge Capital Management, Llc | 2024-12-31 | 2.5 M |
Bioatla Historical Income Statement
Bioatla Stock Against Markets
Bioatla Corporate Management
| Gerhard Frey | Senior Development | Profile | |
| Cathy Chang | Senior Development | Profile | |
| Christian CPA | Controller Officer | Profile | |
| Sheri Lydick | Chief Officer | Profile | |
| Philippe Martin | Chief Operations | Profile | |
| Monica Sullivan | Senior Contracts | Profile | |
| Christian Vasquez | Controller Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share | Quarterly Revenue Growth 0.316 | Return On Assets | Return On Equity |
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioatla is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.